American Journal of Alzheimer's Disease and Other Dementias®

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1533317508317816v1
23/3/274    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Hatzifilippou, E.
Right arrow Articles by Baloyannis, S. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hatzifilippou, E.
Right arrow Articles by Baloyannis, S. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on June 1, 2008
American Journal of Alzheimer's Disease and Other Dementias®, Vol. 23, No. 3, 274-279 (2008)
DOI: 10.1177/1533317508317816

Antibodies Against GM1 in Demented Patients

Eleni Hatzifilippou, MSc

Neuroimmunological Laboratory of the 1st Department of Neurology Aristotelian University, AHEPA Hospital, Thessaloniki, Greece

Ephrosini Koutsouraki, MD

Memory Clinic of the 1st Department of Neurology, Aristotelian University, Neuroimmunological Laboratory of the 1st Department of Neurology Aristotelian University, AHEPA Hospital, Thessaloniki, Greece

Tania Banaki, MSc

Memory Clinic of the 1st Department of Neurology, Aristotelian University

Maria Traka, MD

Memory Clinic of the 1st Department of Neurology, Aristotelian University

Vassiliki G. Costa, MD

Memory Clinic of the 1st Department of Neurology, Aristotelian University, Neuroimmunological Laboratory of the 1st Department of Neurology Aristotelian University, AHEPA Hospital, Thessaloniki, Greece

Stavros J. Baloyannis, MD, PhD

Memory Clinic of the 1st Department of Neurology, Aristotelian University, mpalogia{at}auth.gr, Neuroimmunological Laboratory of the 1st Department of Neurology Aristotelian University, AHEPA Hospital, Thessaloniki, Greece

The aim of this study was to evaluate the levels of anti-GM1 in demented patients, correlating them with the type and severity of dementia as well as with the eventually coexistent polyneuropathy. Anti-GM1 concentrations were measured in the sera of 33 demented patients with a male-to-female ratio of 1:2.7 (the mean age was 69.7 years for males and 70.1 years for females). Eighty-two percent of the patients revealed increased values of anti-GM1, but only 18.2% demonstrated polyneuropathies. Fifty-nine percent of the patients suffered from vascular dementia. The most severely demented patients demonstrated a Mini-Mental State Examination score of 5 to 23 out of 30 and revealed the most increased levels of anti-GM1 (>40 EU/mL). The findings of this study are indicative of a possible correlation between the levels of anti-GM1 and the severity of dementia, mainly of the vascular type.

Key Words: antibodies to GM1 • dementia • anti-GM1 IgM and dementia • gangliosides in dementia • Alzheimer's disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?